FDA Asks Endo To Remove Opana ER, Citing Opioid Crisis
The U.S. Food and Drug Administration took a first-of-its-kind step toward combating the opioid epidemic on Thursday by formally requesting Endo Pharmaceuticals take Opana ER off the market after concluding the...To view the full article, register now.
Already a subscriber? Click here to view full article